Akebia Therapeutics, Inc. (AKBA) Key Metrics
AKBA valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $185.7M
- Enterprise value
- $157.9M
- P/E (TTM)
- —
- Forward P/E
- 28.7
- PEG ratio
- —
- Price / sales
- 0.8 10-yr median 1.8
- Price / book
- 10.3 10-yr median 3.5
- EV / EBITDA
- 64.4
- Dividend yield
- —
- Beta
- 0.18
AKBA key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAKBA valuation Price multiples at each fiscal year-end price.
Price / sales−29.9%
1.8
2025 · hover or tap a bar for each year
20162025
Price / book
12.7
2025 · hover or tap a bar for each year
20162025
EV / EBITDA
20.5
2025 · hover or tap a bar for each year
20162025
Free cash flow yield+26.6 pts
16.4%
2025 · hover or tap a bar for each year
20162025
AKBA returns How much profit the business earns on the capital it uses.
Return on invested capital+91.9 pts
24.5%
2025 · hover or tap a bar for each year
20162025
Return on assets+28.2 pts
−1.8%
2025 · hover or tap a bar for each year
20162025
Free cash flow margin+54.2 pts
28.8%
2025 · hover or tap a bar for each year
20162025
Asset turnover+14.2%
0.79
2025 · hover or tap a bar for each year
20162025
AKBA per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+21.0%
$0.92
2025 · hover or tap a bar for each year
20162025
Earnings per share
−$0.02
2025 · hover or tap a bar for each year
20162025
Free cash flow per share
$0.26
2025 · hover or tap a bar for each year
20162025
Book value per share
$0.13
2025 · hover or tap a bar for each year
20162025
Shares outstanding+21.9%
257.2M
2025 · hover or tap a bar for each year
20162025
AKBA financial health Debt, liquidity and how easily interest is covered.
Debt / equity
6.63
2025 · hover or tap a bar for each year
20162025
Net debt−$105.4M
$31.5M
2025 · hover or tap a bar for each year
20162025
Net debt / EBITDA
1.45
2025 · hover or tap a bar for each year
20162025
Current ratio−19.4%
1.13
2025 · hover or tap a bar for each year
20162025
Interest coverage
1.0
2025 · hover or tap a bar for each year
20162025
Debt / assets−32.8%
0.57
2025 · hover or tap a bar for each year
20162025
AKBA efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−21 days
63 days
2025 · hover or tap a bar for each year
20162025
Days of inventory+55 days
147 days
2025 · hover or tap a bar for each year
20162025
Days payables outstanding+82 days
168 days
2025 · hover or tap a bar for each year
20162025
Cash conversion cycle−48 days
42 days
2025 · hover or tap a bar for each year
20162025
Capex / revenue+0.1 pts
0.1%
2025 · hover or tap a bar for each year
20162025
AKBA valuation history
Fiscal year-endToday10-year median
AKBA returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AKBA debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AKBA cash returned to shareholders
DividendsBuybacksFree cash flow
AKBA price vs earnings per share
Share price at year-endEPS (right axis)
AKBA key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $414.0M | $400.8M | $232.5M | $105.5M | $375.0M | $387.7M | $748.3M | $646.4M | — | — |
| Enterprise value | $445.5M | $537.7M | $293.7M | $114.8M | $414.4M | $244.9M | $708.6M | $339.7M | — | — |
| Price / sales | 1.8 | 2.5 | 1.2 | 0.4 | 1.8 | 1.3 | 2.2 | 3.1 | — | — |
| Price / book | 12.7 | — | — | 20.2 | 5.1 | 1.6 | 1.9 | 1.0 | — | — |
| Price / free cash flow | 6.1 | — | — | — | — | — | — | — | — | — |
| Price / operating cash flow | 6.1 | — | — | — | — | — | — | — | — | — |
| EV / sales | 1.9 | 3.4 | 1.5 | 0.4 | 1.9 | 0.8 | 2.1 | 1.6 | — | — |
| EV / EBITDA | 20.5 | — | — | 37.6 | — | — | — | — | — | — |
| EV / free cash flow | 6.6 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −1.3% | −17.3% | −22.3% | −89.3% | −65.3% | −90.2% | −37.4% | −26.6% | — | — |
| Free cash flow yield | 16.4% | −10.2% | −10.1% | −69.5% | −67.5% | −28.6% | −35.3% | −15.3% | — | — |
| Shareholder yield (dividends + buybacks) | — | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Share price at fiscal year-end | $1.61 | $1.90 | $1.24 | $0.58 | $2.26 | $2.80 | $6.32 | $5.53 | $14.87 | $10.41 |
| Per share | ||||||||||
| Revenue per share | $0.92 | $0.76 | $1.04 | $1.60 | $1.29 | $2.13 | $2.83 | $1.78 | — | — |
| Earnings per share | −$0.02 | −$0.33 | −$0.28 | −$0.52 | −$1.48 | −$2.53 | −$2.36 | −$1.47 | — | — |
| Operating cash flow per share | $0.26 | −$0.19 | −$0.12 | −$0.40 | −$1.52 | −$0.80 | −$2.17 | −$0.83 | — | — |
| Free cash flow per share | $0.26 | −$0.19 | −$0.12 | −$0.40 | −$1.52 | −$0.80 | −$2.23 | −$0.85 | — | — |
| Cash per share | $0.72 | $0.25 | $0.23 | $0.49 | $0.90 | $1.94 | $1.25 | $2.75 | — | — |
| Book value per share | $0.13 | −$0.23 | −$0.16 | $0.03 | $0.45 | $1.79 | $3.33 | $5.44 | — | — |
| Tangible book value per share | −$0.10 | −$0.51 | −$0.67 | −$0.69 | −$0.56 | $0.35 | $0.41 | $2.16 | — | — |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.06 | $0.01 | — | — |
| Debt per share | $0.84 | $0.89 | $0.56 | $0.55 | $1.14 | $0.91 | $0.91 | $0.13 | — | — |
| Shares outstanding | 257.2M | 210.9M | 187.5M | 182.8M | 165.9M | 138.5M | 118.4M | 116.9M | — | — |
| Change in shares outstanding | +21.9% | +12.5% | +2.6% | +10.1% | +19.9% | +16.9% | +1.3% | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | −237.8% | −152.3% | −108.9% | −54.3% | −45.5% | −82.1% | −136.3% |
| Return on invested capital (ROIC) | 24.5% | −67.4% | −161.6% | −99.8% | −192.2% | −129.3% | −66.1% | −213.5% | — | — |
| Return on assets (ROA) | −1.8% | −30.0% | −17.4% | −21.3% | −41.7% | −49.4% | −31.6% | −25.3% | −23.2% | −61.3% |
| Return on tangible assets | −1.7% | −42.9% | −35.4% | −41.9% | −67.6% | −78.6% | −65.8% | −28.0% | −21.1% | −45.2% |
| Free cash flow margin | 28.8% | −25.4% | −12.0% | −25.1% | −118.5% | −37.5% | −78.8% | −47.7% | −32.5% | — |
| Financial health | ||||||||||
| Total debt | $216.3M | $188.7M | $104.2M | $99.8M | $189.1M | $126.3M | $108.3M | $15.0M | $987,000 | $14,000 |
| Cash & short-term investments | $184.8M | $51.9M | $42.9M | $90.5M | $149.8M | $269.1M | $148.0M | $321.6M | $317.8M | $260.3M |
| Net debt | $31.5M | $136.9M | $61.3M | $9.3M | $39.3M | −$142.8M | −$39.6M | −$306.6M | −$316.8M | −$260.3M |
| Debt / equity | 6.63 | — | — | 19.08 | 2.56 | 0.51 | 0.27 | 0.02 | 0.01 | 0.00 |
| Debt / assets | 0.57 | 0.86 | 0.43 | 0.28 | 0.36 | 0.20 | 0.14 | 0.02 | 0.00 | 0.00 |
| Net debt / EBITDA | 1.45 | — | — | 3.05 | — | — | — | — | — | — |
| Current ratio | 1.13 | 1.41 | 1.18 | 1.43 | 1.04 | 1.98 | 1.49 | 1.76 | 2.48 | 2.59 |
| Quick ratio | 1.04 | 1.21 | 1.03 | 1.26 | 0.90 | 1.66 | 0.93 | 1.33 | 2.48 | 2.59 |
| Interest coverage | 1.0 | -2.8 | -7.7 | -5.1 | -13.3 | -42.4 | -7.4 | -28.9 | -28.6 | -151.5 |
| Working capital | $21.9M | $32.9M | $18.3M | $55.6M | $10.1M | $184.3M | $101.4M | $202.6M | $214.0M | $182.1M |
| Invested capital | $64.1M | $87.7M | $30.7M | $14.5M | $113.3M | $104.8M | $355.1M | $329.3M | −$197.5M | −$192.2M |
| Tangible asset value | −$26.4M | −$108.2M | −$125.7M | −$125.9M | −$93.2M | $48.4M | $48.5M | $252.7M | $119.3M | $68.1M |
| Net current asset value | −$159.1M | −$156.0M | −$154.1M | −$165.6M | −$184.2M | −$25.1M | −$66.9M | $107.7M | $113.4M | $64.2M |
| Graham net-net per share | −$0.45 | −$0.87 | −$1.02 | −$1.20 | −$1.50 | −$0.55 | −$1.19 | $0.26 | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | $1.3M | $0 | $0 | $0 | $0 | $426,000 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | — | 0.0% |
| Capex / revenue | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 2.0% | 0.8% | 0.9% | 173.4% |
| Capex / operating cash flow | 0.4% | — | — | — | — | — | — | — | — | 4.6% |
| Capex / depreciation | 0.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.17 | 0.66 | 2.63 | 8.99 |
| Stock-based compensation / revenue | 4.8% | 4.9% | 4.8% | 6.1% | 10.6% | 8.3% | 3.6% | 9.2% | 5.0% | 379.5% |
| R&D / revenue | 26.4% | 23.5% | 32.4% | 56.8% | 69.2% | 74.0% | 96.4% | 140.1% | 129.7% | 7,543.0% |
| SG&A / revenue | 45.5% | 66.5% | 53.2% | 47.4% | 83.2% | 53.3% | 45.7% | 41.9% | 15.2% | 1,446.9% |
| Efficiency | ||||||||||
| Days sales outstanding | 62.9 | 83.9 | 74.6 | 57.3 | 68.5 | 41.7 | 30.3 | 44.7 | 69.8 | 8,042.6 |
| Days of inventory on hand | 147.3 | 92.2 | 91.7 | 472.1 | 116.2 | 109.4 | 289.6 | 2,713.0 | 0.0 | — |
| Days payables outstanding | 168.2 | 86.1 | 80.4 | 418.7 | 89.1 | 49.7 | 103.0 | 1,182.5 | 2,673.0 | 6.9 |
| Cash conversion cycle (days) | 42.0 | 90.0 | 85.9 | 110.8 | 95.6 | 101.4 | 216.8 | 1,575.3 | -2,603.3 | 8,035.7 |
| Receivables turnover | 5.80 | 4.35 | 4.89 | 6.37 | 5.33 | 8.76 | 12.07 | 8.17 | 5.23 | 0.05 |
| Payables turnover | 2.17 | 4.24 | 4.54 | 0.87 | 4.10 | 7.35 | 3.54 | 0.31 | 0.14 | 53.21 |
| Inventory turnover | 2.48 | 3.96 | 3.98 | 0.77 | 3.14 | 3.34 | 1.26 | 0.13 | 1,234,000.00 | — |
| Asset turnover | 0.79 | 0.69 | 0.65 | 0.66 | 0.36 | 0.42 | 0.38 | 0.31 | 0.54 | 0.01 |
| Average receivables | $40.7M | $36.8M | $39.8M | $45.9M | $40.1M | $33.7M | $27.8M | $25.4M | $34.0M | $33.8M |
| Average payables | $18.2M | $14.9M | $16.3M | $25.8M | $37.4M | $40.3M | $41.0M | $24.9M | $4.5M | $2.2M |
| Average inventory | $15.9M | $16.0M | $18.6M | $29.1M | $48.8M | $88.7M | $115.3M | $57.1M | $0 | $0 |
| Intangibles / total assets | 15.7% | 26.8% | 39.3% | 36.8% | 31.6% | 30.9% | 44.9% | 38.5% | 0.0% | 0.0% |
Computed from AKBA's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AKBA valuation and financial ratios
Akebia Therapeutics earned a return on invested capital of 24.5% in fiscal 2025. It ended the year with $216.3 million of debt and $184.8 million in cash and short-term investments, net debt of $31.5 million.
See the AKBA income statement, the AKBA chart for price history, or the AKBA stock overview for the latest quote and news.
AKBA key metrics FAQ
What is Akebia Therapeutics's EV/EBITDA?
Akebia Therapeutics's enterprise value was 20.5 times EBITDA at the end of fiscal 2025 (enterprise value $445.5 million, EBITDA $21.7 million); the current EV/EBITDA is 64.4.
What is Akebia Therapeutics's ROIC?
Akebia Therapeutics's return on invested capital was 24.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Akebia Therapeutics have?
Akebia Therapeutics had total debt of $216.3 million at the end of fiscal 2025, a debt-to-equity ratio of 6.63 and $31.5 million of net debt (1.45 times EBITDA).
What is Akebia Therapeutics's free cash flow yield?
Akebia Therapeutics generated $68.0 million of free cash flow in fiscal 2025, a free cash flow yield of 16.4% on its market value at year-end ($414.0 million).
What is Akebia Therapeutics's current ratio?
Akebia Therapeutics's current ratio was 1.13 at the end of fiscal 2025: current assets were 1.13 times current liabilities.